Atlas Trials

A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients

Clinical trial NCT01210768 · UNKNOWN

Trial details

NCT number
NCT01210768
Sponsor
TTY Biopharm
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2010-06-01
Primary completion
2022-10-31
Enrollment
254

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.